Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
about
Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patientsGraft-versus-host disease: why have we not made more progress?Current and emerging strategies for the prevention of graft-versus-host diseaseAdvances in predicting acute GVHDAcute graft-versus-host disease: a bench-to-bedside update.The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseCurrent and future approaches for control of graft-versus-host disease.In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase.Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Improved survival after acute graft-versus-host disease diagnosis in the modern era.The biology of graft-versus-host disease: experimental systems instructing clinical practice.High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationHigh incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease.Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrPathogenesis and management of graft-versus-host disease.Novel regulatory therapies for prevention of Graft-versus-host disease.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Randomised, double-blind, placebo-controlled trial of oral budesonide for prophylaxis of acute intestinal graft-versus-host disease after allogeneic stem cell transplantation (PROGAST).Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized studyAnti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.HDAC inhibition and graft versus host diseaseA retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.High-dose cyclophosphamide for graft-versus-host disease prevention.Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis.Risk factors for acute GVHD and survival after hematopoietic cell transplantationFlagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunityAssociation between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation.Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host diseaseVariation in management of immune suppression after allogeneic hematopoietic cell transplantation.Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysisEvaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host diseasePrior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
P2860
Q26996051-D6B20560-14E0-433D-B735-662DCD3B2563Q27012940-C0DD6D68-2AC1-42D6-9247-8FDD18138DF7Q27016541-CA3E3DAB-5D1A-429B-A5EA-34D9CF609955Q27021123-9340560E-A3DE-4D87-81D6-9670BFBAD37CQ27687130-E9C2E14B-60EA-4AF5-85B5-6C4D38AE7DD5Q28076264-31C5B6B1-7EB6-41B4-AC3A-C3E39D9A54CAQ33642625-C522E7C6-714D-4E4A-8BC7-891FF7D4204DQ33647732-21040EE8-14C6-4E33-A515-6BBFE6E59E6FQ33800533-02486265-FB2A-4685-9F3A-C3840953C035Q33806054-98520546-ECC4-44A3-8ABD-A60C693755C8Q33816027-2CBA3370-599E-4374-B157-DAE3FE266D58Q33917175-7CA92A58-F516-4602-BDC0-30A14DC626D4Q33941128-2063DFAD-3AC4-4A59-873A-03ADC3304372Q33950015-DA056E04-DB89-46B3-841D-E7CED22E9DFEQ33964687-DBA37885-E924-434B-B402-98355F1B7110Q33999284-156D3899-3BFC-4EF7-A65B-B6CF4366F848Q34044024-C4B8C4C4-8B81-496F-B94B-F4EDDE7B5ACCQ34077479-E843672B-8683-4149-9D7A-85A84C106A51Q34269481-D0DBB63D-33A8-4393-B7F9-EB40930E4557Q34272554-AC71E35E-CA79-445D-B510-FCF09BB6BBECQ34649548-9504755A-4865-4AF2-9A32-404C4CAAF8F8Q34666851-3F4B906C-B096-4B04-97C7-07E3F23CF988Q34679045-47F533F8-5D28-485D-9303-5CC540A0FD8FQ34684038-C85C76E0-75F4-4CD2-8337-AAF2F4FF6CC4Q34834459-3863CAB0-877F-41AD-B4F4-E349DD86E82BQ34996663-E23F3358-8A74-4EE2-8413-6FEBA75BC5FAQ35016985-508EA328-ACD6-472C-AC14-ED8BAC768102Q35042830-3F79106B-C312-43AA-A04C-ABDB44172169Q35094029-09C8780C-037C-4E49-ACCC-89F12C77433CQ35110765-6BA1A72D-6CEA-4728-A5CE-48EB4349CF25Q35499395-374101A5-148B-4371-A5E4-821962E23530Q35651735-090304F0-C629-425F-9DF6-D1749BA72D5BQ35691842-E41C90B5-32D7-4B42-8495-D6497DB366B9Q35748508-C76E56CD-532C-49C4-AAD7-4278C00F9BF1Q35800856-49732643-283A-4F16-8DFB-C2407457184FQ35836321-C47E47DC-C810-405A-9143-02498A0E7453Q35848407-62E84E5C-E913-47E0-A30F-817024FC9DBCQ35900978-BDE697F3-491F-47E9-8C63-1427AB8F9BC7Q35903189-C855CF96-4E3F-4B70-BD1D-945B9643CCADQ35970489-5D3AC977-2F38-47A2-9666-F657C4654841
P2860
Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Phase III study comparing meth ...... g bone marrow transplantation.
@en
Phase III study comparing meth ...... g bone marrow transplantation.
@nl
type
label
Phase III study comparing meth ...... g bone marrow transplantation.
@en
Phase III study comparing meth ...... g bone marrow transplantation.
@nl
prefLabel
Phase III study comparing meth ...... g bone marrow transplantation.
@en
Phase III study comparing meth ...... g bone marrow transplantation.
@nl
P2093
P1433
P1476
Phase III study comparing meth ...... g bone marrow transplantation.
@en
P2093
Christiansen NP
Fitzsimmons WE
P304
P407
P577
1998-10-01T00:00:00Z